PDCD1 and neoplasm: An anti-programmed cell death protein 1 (PD-1) antibody drug, pembrolizumab, for advanced/recurrent deficient DNA mismatch repair (dMMR) solid cancers and tropomyosin receptor kinase (TRK) inhibitors against neurotrophic receptor tyrosine kinase (NTRK) fusion gene-positive advanced solid cancers were approved in tumor-agnostic therapy [3].